Double-Blind , Placebo-Controlled Randomized Phase II Study of Hangeshashinto for Prevention of Oral Mucositis in Colorectal Cancer Patients Receiving Chemotherapy (HANGESHA-C Study).
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals. Oral administration of Placebo 7.5g/day t.i.d. after meals. Primary outcome(s): Incidence of oral mucositis. grade>=2 Study Design: Parallel Randomized
创建时间：
2010-10-15
